The phrase "at the time of approval" is correct and usable in written English.
It can be used to refer to a specific moment when something was approved, often in legal, formal, or procedural contexts.
Example: "The terms of the contract were established at the time of approval, ensuring all parties understood their obligations."
Alternatives: "when approval was granted" or "at the moment of approval".
A separate study published this week by US watchdog group International Rivers argues that nearly three quarters of all registered CDM projects were complete at the time of approval, suggesting that CDM money was not needed to finance them.
The purpose of this evaluation was to confirm consistency of the dissolution profiles with those of the original product found at the time of approval.
No patient selection based on mutation analysis was performed at the time of approval and all eligible NSCLC patients were treated with erlotinib [14].
Despite the large scale of the project, it appears that critical scientific data required to resolve uncertainties and construct robust models of the springs' relationship to the groundwater system were lacking at the time of approval, contributing to uncertainty and conflict.
Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development.
Consider, for example, the FDA's approval in 1976 of the swine flu vaccine, generally perceived to have been a Type I error, because although the vaccine was effective at preventing influenza, it went on to manifest a major side effect that was unknown at the time of approval: 532 cases of paralysis, including 32 deaths, from Guillain-Barré syndrome.
Drugs granted orphan drug designation at the time of original approval were subsequently approved for 77 supplemental indications, 40 (52%) of which were indications not related to rare diseases.
The pharmaceutical industry has a poor track record of getting the dose right at the time of product approval, with about 80% of drugs having a reduction in dose within 2 6.5 years after approval.
As a result, a biologic is often still in a relatively early research stage at the time of FDA approval.
The goal of this study was to describe trends in pregnancy labeling at the time of drug approval and over time.
Even in future health economic evaluations it will be difficult to eliminate this limitation as such long-term data on the AVD function will not be available at the time of marketing approval; such data may be available a long time after marketing if the post-marketing surveillance works well.
